RE: Praluent (Alirocumab)-Induced Renal Injury
- PMID: 28974137
- PMCID: PMC5844452
- DOI: 10.1177/0897190017734429
RE: Praluent (Alirocumab)-Induced Renal Injury
Keywords: acute renal injury; alirocumab; rosuvastatin.
Comment on
-
Praluent (Alirocumab)-Induced Renal Injury.J Pharm Pract. 2017 Feb;30(1):7-8. doi: 10.1177/0897190016683304. Epub 2016 Dec 14. J Pharm Pract. 2017. PMID: 28093956 No abstract available.
References
-
- Jhaveri KD, Barta VS, Pullman J. Praluent (alirocumab)-induced renal injury. J Pharm Pract. 2017;30(1):7–8. - PubMed
-
- CRESTOR (rosuvastatin calcium) [package insert]. AstraZeneca Pharmaceuticals LP. https://www.azpicentral.com/crestor/crestor.pdf#page=1. Accessed May 5, 2017.
-
- Ward FL, Bargman JM, McQuillan RF. Renal tubular toxicity associated with rosuvastatin therapy. Am J Kidney Dis. 2017;69(3):473–476. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
